Basic Information

Gene symbol E2F1 Synonyms E2F-1, RBAP1, RBBP3, RBP3 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description E2F transcription factor 1

Gene symbol SPAM1 Synonyms HEL-S-96n, HYA1, HYAL1, HYAL3, HYAL5, PH-20, PH20, SPAG15 Type of gene protein-coding
Description sperm adhesion molecule 1

GTO ID GTC3985
Trial ID NCT03799744
Disease Head and Neck Carcinoma
Altered gene E2F1|PH20
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment VCN-01
Co-treatment Durvalumab
PhasePhase1
Recruitment statusUnknown
TitleA Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
Year2019
CountrySpain
Company sponsorInstitut Català d'Oncologia
Other ID(s)ICO-VCN-H&N-2018|2018-001095-38
Vector information
Vectoradenovirus
ConstructAd5-E2F-delta24-RGD -PH20
Vector typeoncolytic adenovirus (Ad5 based)
Transgene/Inserted geneHyaluronidase (PH20), which enables the virus to degrade the extracellular matrix, disrupt the tumor stroma, thus enhancing the intratumoral spreading of the virus.
Viral genome modificationVCN-01 incorporates an RGKD integrin motif in the fiber shaft, an effective method for liver detargeting and tumor retargeting.
Additional featureHyaluronidase (PH20)

Clinical Result

Cohort1: dose level 1
Administration route intravenous injection
Dosage VCN-01, 3.3E12 viral particles/patient
Age Adult, Older_Adult
Cohort2: dose level 2
Administration route intravenous injection
Dosage VCN-01, 1E13 viral particles/patient
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph